Panel, Conference Presentation
Bending the Cost Curve: Understanding the GLP-1 Era | Global Conference 2025
- Cost Trajectory and Timeframes: Experts project an initial period of rising costs followed by a bending of the cost curve starting in the second year of GLP-1 adherence, with full curve stabilization and significant cost reductions anticipated within three years. Long-term projections suggest drug costs will eventually drop to generic statin levels, a transition expected to occur within 10 to 20 years, driven by market competition and the shift from injectable to pill forms.
- Employer Strategy and Retention: Employers are expected to face immediate pressure to provide GLP-1 coverage, viewing the $10,000 annual cost as a critical retention and recruitment tool comparable to a $600 to $700 monthly out-of-pocket burden that currently drives employees to seek new jobs or use dangerous black market alternatives. Aon anticipates a return on investment (ROI) for this expenditure, supported by data from a 50 million-person database and a specific cohort of 139,000 adherents, aiming to validate the benefits of a healthier, more productive workforce.
- Market Disruption and Regulatory Shifts: A "traumatic" market correction is forecasted for the end of Q4 or the subsequent summer and fall when FDA regulations eliminate counterfeit drugs, forcing a transition from cheap or illegal access points to legitimate, employer-sponsored programs. This shift is expected to create a population of 1.5 million individuals seeking affordable access upon losing counterfeit options, while legal mandates may soon require coverage for new indications including liver, kidney, and cardiovascular diseases.
- Operational Efficiency and Adherence: The implementation of AI, telehealth, and remote monitoring is predicted to reduce clinical management time per patient from over 100 hours to approximately 12 hours, removing administrative friction. Specialized programs utilizing community support, daily check-ins, and biological "report cards" are projected to increase adherence rates to 98%, addressing the current 50% dropout rate observed within 90 days.
- Systemic Risks and Barriers: Key risks include the persistence of "obesity discrimination" as a primary barrier to coverage and reimbursement, which may stifle adoption even at lower price points like £100 per month in the UK. Additionally, the absence of employer support could lead to severe financial strain on individuals, potentially forcing them to sacrifice housing or food, while the long-term fiscal impact on Social Security and Medicare remains uncertain due to variables like extended working lives and reduced disability claims.